Adaptive Designs for Clinical Trials in Nephrology.
Rathika Krishnasamy, Meg J Jardine, BEAT-Calci Trialists
https://pubmed.ncbi.nlm.nih.gov/39186385/Actively Recruiting
Led by University of Sydney · Updated on 2025-08-13
350
Participants Needed
21
Research Sites
N/A
Total Duration
Researchers are evaluating several treatments for adults with kidney failure who have recently been diagnosed with calciphylaxis, a rare disease affecting about 1 to 2 people in 10,000. This phase 3 global platform trial aims to provide high-quality evidence on the effects of different therapies across various care areas. The study uses an adaptive design to add or remove treatment options based on ongoing results, improving how patients with this condition are treated. The trial begins with two main treatment areas the Dialysis Membrane Domain and the Pharmacotherapy Domain. In the Pharmacotherapy Domain, participants receive either Vitamin K1 capsules, Magnesium Citrate tablets, Sodium Thiosulfate injections, or placebos, with dosing schedules matched to their dialysis sessions. The Dialysis Membrane Domain compares two types of dialysis filters, high flux and medium cut-off dialysers, in an open-label design. Treatments are given according to these schedules, and new interventions may be added as the trial progresses. Participants will be monitored and assessed using the BEAT-Calci Wound Assessment Scale over 12 weeks as the primary outcome, with additional evaluations up to 26 weeks and beyond. Assessments include wound measurements, pain levels, analgesic use, quality of life, infection rates, hospital days, mortality, kidney transplantation status, and calciphylaxis recurrence. The study uses a Bayesian adaptive approach to adjust sample size and study arms based on collected data, continuing until clear results on treatment effects are reached.
CONDITIONS
Better Evidence and Translation for Calciphylaxis
S
Sibyl Masterman
M
Meg Jardine
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Sydney
Lead Sponsor
Australasian Kidney Trials Network
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 weeks
Participants receive assigned interventions including drug treatments administered orally or intravenously and device interventions involving different dialysis membranes while undergoing hemodialysis sessions.
3 visits per week during hemodialysis sessions
Duration - Up to 5 years
Participants are monitored for outcomes related to wound healing, pain, quality of life, infections, hospitalizations, and survival up to 26 weeks post-treatment, with some outcomes followed up to 5 years.
Periodic assessments including visits at Weeks 4, 12, and 26
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Have more questions? Get in touch with our team for quick support
Rathika Krishnasamy, Meg J Jardine, BEAT-Calci Trialists
https://pubmed.ncbi.nlm.nih.gov/39186385/University of Sydney
Lead Sponsor
Australasian Kidney Trials Network
Collaborating Sponsor